NO750579L - - Google Patents
Info
- Publication number
- NO750579L NO750579L NO750579A NO750579A NO750579L NO 750579 L NO750579 L NO 750579L NO 750579 A NO750579 A NO 750579A NO 750579 A NO750579 A NO 750579A NO 750579 L NO750579 L NO 750579L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compounds
- methyl
- acid
- benzo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 42
- 239000002253 acid Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 238000009835 boiling Methods 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- -1 benzene Chemical class 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- VOBWLFNYOWWARN-UHFFFAOYSA-N thiophen-3-one Chemical compound O=C1CSC=C1 VOBWLFNYOWWARN-UHFFFAOYSA-N 0.000 description 3
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 2
- WYJOVVXUZNRJQY-UHFFFAOYSA-N 2-Acetylthiophene Chemical compound CC(=O)C1=CC=CS1 WYJOVVXUZNRJQY-UHFFFAOYSA-N 0.000 description 2
- MYGXGCCFTPKWIH-UHFFFAOYSA-N 4-chloro-1-methylpiperidine Chemical compound CN1CCC(Cl)CC1 MYGXGCCFTPKWIH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 229960005333 tetrabenazine Drugs 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- YDFXKRLGZYFXOE-UHFFFAOYSA-N 2-(diethoxyphosphorylmethyl)benzonitrile Chemical compound CCOP(=O)(OCC)CC1=CC=CC=C1C#N YDFXKRLGZYFXOE-UHFFFAOYSA-N 0.000 description 1
- WVYWICLMDOOCFB-UHFFFAOYSA-N 4-methyl-2-pentanol Chemical compound CC(C)CC(C)O WVYWICLMDOOCFB-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229940008309 acetone / ethanol Drugs 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000002903 catalepsic effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- MWWHYPORGYMFIP-UHFFFAOYSA-N cyclohepta[b]thiophen-4-one Chemical compound O=C1C=CC=CC2=C1C=CS2 MWWHYPORGYMFIP-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 231100000546 inhibition of ovulation Toxicity 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical compound [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WJIBZZVTNMAURL-UHFFFAOYSA-N phosphane;rhodium Chemical class P.[Rh] WJIBZZVTNMAURL-UHFFFAOYSA-N 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000026234 pro-estrus Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical compound [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910001023 sodium amalgam Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000011949 solid catalyst Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Plural Heterocyclic Compounds (AREA)
Description
Foreliggende oppfinnelse vedrorer en fremgangsmåte for fremstilling av nye forbindelser med formel I The present invention relates to a method for the production of new compounds with formula I
hvori betyr hydrogen, klor eller lavere alkyl, R_ står for lavere alkyl, R^betyr lavere alkyl, A og B står hver for hydrogen eller danner sammen en binding, og syreaddisjonssalter derav. wherein means hydrogen, chlorine or lower alkyl, R_ stands for lower alkyl, R^ means lower alkyl, A and B each stand for hydrogen or together form a bond, and acid addition salts thereof.
Det særegne ved fremgangsmåten i henhold til oppfinnelsen er at vann avspaltes fra forbindelser med formel II The distinctive feature of the method according to the invention is that water is separated from compounds of formula II
"hvori R^, R2/ R3/ A og B har den ovennevnte betydning, og de erholdte forbindelser med formel I overfores eventuelt i sine syreaddisjonssalter. I forbindelsene med formel I betyr R^foretrukket hydrogen. Mulige substituenter R^er foretrukket anordnet i 6- eller 8-stillingen av ringskjelettet. Hvis R^ betyr lavere alkyl, inneholder dette foretrukket 1 til 3 karbonatomer og utgjore spesielt metyl. Den ved R2 symboliserte lavere alkylgruppe har foretrukket 1 til 4 karbonatomer og utgjor spesielt metylgruppen. Den ved R^symboliserte lavere alkylgruppe har foretrukket 1 til 4 karbonatomer og utgjor spesielt metylgruppen. Foretrukket står A og B for hydrogen. Spesielt foretrukket er f.eks. forbindelser hvori R^ betyr hydrogen og R2står for metyl, idet A og B hver betyr hydrogen og R^betyr lavere alkyl, foretrukket metyl. "in which R^, R2/R3/ A and B have the above meaning, and the obtained compounds of formula I are optionally transferred in their acid addition salts. In the compounds of formula I, R^ preferably means hydrogen. Possible substituents R^ are preferably arranged in 6 - or the 8-position of the ring skeleton. If R^ means lower alkyl, this preferably contains 1 to 3 carbon atoms and constitutes especially methyl. The lower alkyl group symbolized by R2 preferably has 1 to 4 carbon atoms and constitutes especially the methyl group. The lower alkyl group symbolized by R^ alkyl group preferably has 1 to 4 carbon atoms and in particular constitutes the methyl group. Preferably A and B stand for hydrogen. Particularly preferred are, for example, compounds in which R^ stands for hydrogen and R2 stands for methyl, with A and B each standing for hydrogen and R^ stands for lower alkyl, preferably methyl.
Fremgangsmåten for vannavspaltingen fra forbindelsene med formel II kan gjennomfores på for analoge karbinoler kjent måte, f.eks. ved innvirkning av egnede vannavspaltende midler på forbindelsene med formel II, eventuelt under tilsetning av et under reaksjonsbetingelsene inert organisk losningsmiddel, f.eks. en lavere alkohol. Som vannavspaltende middel kan anvendes f.eks. minereal- syrer eller sterke organiske syrer, f.eks. alkoholiske hydrogen-kloridlosninger, konsentrert saltsyre/iseddik, trifluoreddiksyre, benzensulfonsyre eller også syreanhydrider eller syrehalogenider som f.eks. eddiksyreanhydrid eller tionylklorid. Vannavspaltingen skjer foretrukket ved temperatur mellom ca. 0 og 100°C. The procedure for the removal of water from the compounds of formula II can be carried out in a manner known for analogous carbinols, e.g. by the action of suitable water-splitting agents on the compounds of formula II, optionally with the addition of an organic solvent inert under the reaction conditions, e.g. a lower alcohol. As a water-splitting agent can be used, e.g. mineral acids or strong organic acids, e.g. alcoholic hydrogen chloride solutions, concentrated hydrochloric acid/glacial acetic acid, trifluoroacetic acid, benzenesulfonic acid or also acid anhydrides or acid halides such as e.g. acetic anhydride or thionyl chloride. The water splitting takes place preferably at a temperature between approx. 0 and 100°C.
Forbindelsene med formel I kan på i og for seg kjent måte isoleres fra reaksjonsblandingeh og renses. De fri baser lar seg på vanlig måte overfore i sine syreaddisjonssalter og omvendt. The compounds of formula I can be isolated from the reaction mixture and purified in a manner known per se. The free bases can be converted in the usual way into their acid addition salts and vice versa.
Utgangsforbindelsene kan f.eks. fremstilles på fSigende måte:The output connections can e.g. produced in the following manner:
a) Forbindelsene med formel II kan f.eks. fremstilles ved at forbindelser med formel III a) The compounds of formula II can e.g. are produced by compounds of formula III
hvori R1, R2, A og B har den ovennevnte betydning, omsettes med en metallorganisk forbindelse med formel X wherein R1, R2, A and B have the above meaning, is reacted with an organometallic compound of formula X
hvori R- har den ovennevnte betydning og Z star for litium eller wherein R- has the above meaning and Z stands for lithium or
II II
en halogenmagnesiumrest -MgX , hvori X betyr klor, brom eller jod, og reaksjonsproduktet hydrolyseres. a halogen magnesium residue -MgX, where X means chlorine, bromine or iodine, and the reaction product is hydrolysed.
Fremgangsmåten kan foretrukket gjennomføres i et for Grinard-reaksjoner egnet organisk losningsmiddel, f.eks. en eter som dietyleter eller tetrahydrofuran og eventuelt et aromatisk hydrokarbon som benzen, ved temperaturer mellom -20 og 80°C, foretrukket ved temperaturer mellom 20 og 50°C. Hydrolysen av det som mellomprodukt dannede meta11organiské kompleks kan skje på i og for seg kjente måte, f.eks. med vandig ammoniumkloridlosning. The method can preferably be carried out in an organic solvent suitable for Grinard reactions, e.g. an ether such as diethyl ether or tetrahydrofuran and optionally an aromatic hydrocarbon such as benzene, at temperatures between -20 and 80°C, preferably at temperatures between 20 and 50°C. The hydrolysis of the meta11organic complex formed as an intermediate can take place in a manner known per se, e.g. with aqueous ammonium chloride solution.
b) Forbindelser?med formel Illab) Compounds?with formula Illa
hvori R^og R2 har den ovennevnte betydning, kan f.eks. fremstilles ved at forbindelser med formel Illb hvori og R2har den ovennevnte betydning, bromeres og fra de erholdte forbindelser med formel IV hvori R^, og R2har den ovennevnte betydning og bromatomet er i 9- eller 10-stillingen, avspaltes hydrogenbromid. Bromeringen av forbindelsen med formel Illb kan skje f.eks. ved omsetning med den teoretiske mengde av et bromeringsmiddel som f.eks. N-bromsukkinimid, foretrukket under katalytisk innvirkning av et peroksyd som f.eks. benzoylperoksyd, i nærvær av et under reaksjonsbetingelsene inert organisk løsningsmiddel. Som løsningsmiddel egner seg foretrukket halogenerte hydrokarboner som f.eks. karbontetraklorid. Reaksjonstemperaturen kan utgjore mellom ca. 20°C og koketemperaturen for reaksjonsblandingen. Hydrogenbromidavspaltingen fra forbindelsene med formel IV kan skje under alkaliske reaksjonsbetingelser. Den kan f.eks. gjennomføres ved hjelp av en organisk base som f.eks. trietylamin eller pyridin eller en uorganisk base, eventuelt under tilsetning av et under reaksjonsbetingelsene inert organisk løsningsmiddel, ved temperaturer mellom ca. 0 og 100°C. Som løsningsmiddel egner seg f.eks. klorerte hydrokarboner, aceton eller aromatiske hydrokarboner som benzen eller toluen. c) Forbindelser med formel Illb kan f.eks. fremstilles ved at forbindelser med formel V hvori R^ og R2har den^ovennevnte betydning, ringsluttes. Ringslutningen av forbindelsene med formel V skjer foretrukket i nærvær av en sterk sur katalysator, f.eks. en sterk mineral-syre som foretrukket polyfosforsyre eller svovelsyre, eventuelt under tilsetning av et under reaksjonsbetingelsene inert organisk løsningsmiddel, f.eks. et hydrokarbon som toluen eller xylen. Reaksjonstemperaturen ligger foretrukket mellom 50 og 160°C og reaksjonstiden utgjor mellom 5 min. og 10 timer. I stedet for en syre med formel V kan f.eks. også reaksjonsdyktige derivater av denne syre anvendes for ringslutningen. Som reaksjonsdyktige derivater egner seg f.eks. syrehalogendider eller syreanhydrider men også lavere alkylestere av syrene med formel V. Etter en fremgangsmåte-variant kan f.eks. syrene med formel V forst overfores i sine syreklorider med et uorganisk syreklorid som f.eks. tionylklorid og disse deretter ringsluttes under reaksjonsbetingelsene for en Friedel-kraftreaksjon i nærvær av en Friedel-kraftskatalysator som aluminiumklorid i et under reaksjonsbetingelsene inert organisk løsningsmiddel. d) Forbindelsene med formel V kan f.eks. fremstilles ved reduksjon av forbindelser med formel VI in which R 1 and R 2 have the above meaning, can e.g. are prepared by brominating compounds of formula IIIb in which and R2 have the above meaning, and from the obtained compounds of formula IV in which R1 and R2 have the above meaning and the bromine atom is in the 9- or 10-position, hydrogen bromide is split off. The bromination of the compound of formula IIIb can take place e.g. by reaction with the theoretical amount of a brominating agent such as e.g. N-bromosuccinimide, preferably under the catalytic action of a peroxide such as e.g. benzoyl peroxide, in the presence of an organic solvent inert under the reaction conditions. Halogenated hydrocarbons such as e.g. carbon tetrachloride. The reaction temperature can be between approx. 20°C and the boiling temperature of the reaction mixture. The hydrogen bromide separation from the compounds of formula IV can take place under alkaline reaction conditions. It can e.g. carried out using an organic base such as e.g. triethylamine or pyridine or an inorganic base, possibly with the addition of an organic solvent inert under the reaction conditions, at temperatures between approx. 0 and 100°C. As a solvent, e.g. chlorinated hydrocarbons, acetone or aromatic hydrocarbons such as benzene or toluene. c) Compounds of formula IIIb can e.g. are produced by ring-closing compounds of formula V in which R 1 and R 2 have the above-mentioned meaning. The cyclization of the compounds of formula V takes place preferably in the presence of a strong acid catalyst, e.g. a strong mineral acid, preferably polyphosphoric acid or sulfuric acid, optionally with the addition of an organic solvent inert under the reaction conditions, e.g. a hydrocarbon such as toluene or xylene. The reaction temperature is preferably between 50 and 160°C and the reaction time is between 5 min. and 10 hours. Instead of an acid of formula V, e.g. reactive derivatives of this acid are also used for the ring closure. As reactive derivatives, e.g. acid halides or acid anhydrides but also lower alkyl esters of the acids with formula V. According to a method variant, e.g. the acids of formula V are first transferred in their acid chlorides with an inorganic acid chloride such as e.g. thionyl chloride and these are then cyclized under the reaction conditions for a Friedel force reaction in the presence of a Friedel force catalyst such as aluminum chloride in an organic solvent inert under the reaction conditions. d) The compounds of formula V can e.g. are produced by reduction of compounds of formula VI
hvori R, og R2har den ovennevnte betydning. Reduksjonen av forbindelsene med formel VI kan f.eks. gjennomfores med naskerende hydrogen, f.eks. ved behandling av>forbindelsene med formel VI med natriumamalgam/alkohol. Reduksjonen kan også skje ved katalytisk hydrogenering. Den katalytiske hydrogenering kan f.eks. gjennomfores i nærvær av en fast katalysator, f.eks. wherein R, and R2 have the above meaning. The reduction of the compounds of formula VI can e.g. is permeated with nascent hydrogen, e.g. by treating the compounds of formula VI with sodium amalgam/alcohol. The reduction can also take place by catalytic hydrogenation. The catalytic hydrogenation can e.g. is carried out in the presence of a solid catalyst, e.g.
en palladium-katalysator på i og for seg kjent måte i et under reaksjonsbetingelsene inert løsningsmiddel, i dimetylformamid eller en lavere alkohol ved temperaturer mellom foretrukket 30 a palladium catalyst in a manner known per se in a solvent inert under the reaction conditions, in dimethylformamide or a lower alcohol at temperatures between preferably 30
og 100°C ved 5 - 100 atmosfærer hydrogentrykk eller ved inn-ledning av hydrogen i reaksjonsblandingen. Som katalysator for hydrogeneringen egner seg f.eks. også organiske fosfin-rodiumkomplekser. Således kan forbindelsene med formel VI hydrogeneres f.eks. under anvendelse av tris-(trifenylfosfin) rodiumklorid som katalysator i alkoholisk losning ved ca. 1 til 6 atmosfærer hydrogentrykk og ved en reaksjonstemperatur på and 100°C at 5 - 100 atmospheres of hydrogen pressure or by introducing hydrogen into the reaction mixture. As a catalyst for the hydrogenation, e.g. also organic phosphine-rhodium complexes. Thus, the compounds of formula VI can be hydrogenated, e.g. using tris-(triphenylphosphine)rhodium chloride as catalyst in alcoholic solution at approx. 1 to 6 atmospheres of hydrogen pressure and at a reaction temperature of
ca. 40 til 60°C.about. 40 to 60°C.
e) Forbindelsene med formel VI kan f;i:eks. fremstilles ved at forbindelser med formel VI e) The compounds with formula VI can, for example, is produced by compounds of formula VI
hvori og R2har den ovennevnte betydning, hydrolyseres. Hydrolysen gjennomfores foretrukket i alkalisk medium, f.eks. med kalium- eller natriumhydroksyd i hoytkokende alkoholer som f.eks. metylisobutylkarbinol eller n-butanol, ved f.eks. koketemperaturen for reaksjonsblandingen. f) Forbindelser med formel VII kan f.eks. fremstilles ved at et dialkyl-(o-cyanbenzyl)4fosfonat med formel VIII hvori R^ har den ovennevnte betydning og R^betyr lavere alkyl, kondenseres med et alkyl-2-tiofenketon med formel IX hvori R2har den ovennevnte betydning. Omsetningen kan f.eks. skje under reaksjonsbetingelsene for en etter Horner modifisert Wittig-reaksjonen, i ett under reaksjonsbetingelsene inert organisk løsningsmiddel i nærvær av et sterkt basisk kondensasjonsmiddel. Som løsningsmiddel egner seg foretrukket dimetylformamid, eventuelt fortynnet med lavere alkoholer eller etere, f.eks. 1,2-dimetoksyetan. Som basisk kondensasjonsmiddel egner seg foretrukket alkalimetallalkoholater henholdsvis -hydrider, spesielt -natriumetylat, -metylat eller -hydrid eller kalium-tert. -butylat. Reaksjonstemperaturen kan utgjore 20 til 150°C. wherein and R2 has the above meaning, is hydrolyzed. The hydrolysis is preferably carried out in an alkaline medium, e.g. with potassium or sodium hydroxide in high-boiling alcohols such as methylisobutylcarbinol or n-butanol, by e.g. the boiling temperature of the reaction mixture. f) Compounds with formula VII can e.g. is prepared by condensing a dialkyl-(o-cyanobenzyl)4phosphonate of formula VIII in which R^ has the above meaning and R^ means lower alkyl, with an alkyl-2-thiophene ketone of formula IX in which R 2 has the above meaning. The turnover can e.g. take place under the reaction conditions for a Horner-modified Wittig reaction, in an organic solvent inert under the reaction conditions in the presence of a strongly basic condensing agent. The preferred solvent is dimethylformamide, optionally diluted with lower alcohols or ethers, e.g. 1,2-dimethoxyethane. Alkali metal alcoholates or hydrides, especially sodium ethylate, methylate or hydride or potassium tert. -butylate. The reaction temperature can be 20 to 150°C.
Forbindelsene med formel I og deres farmakologisk tålbare syreaddisjonssalter er tidligere ikke beskrevet i litteraturen. De utmerker seg ved interessante farmakodynamiske egenskaper og kan 'folgelig anvendes som legemiddel. Spesielt er forbindelsene med formel I i stand til å hemme sekresjonen av det luteiniserende hormon. Ved funksjonell ovulasjons-hemmingsprove i rotter horer således forbindelsene med formel I doser på 0,05 til 0,5 mg/kg tilfort ved middagstid proostrusdagen til virginale rotter til hemming av den under folgende natt ventede ovulasjon. På grunn av deres hemmende virkning på sekresjonen av det luteiniserende hormon kan substansene anvendes for påvirkning av funksjonene i eggstokk eller testikkel henholdsvis derav avhengige organ-funksjoner, f.eks. for påvirkning av prostata. De doser som anvendes varierer selvfolgelig alt etter art og substans, tilforselsmåte og den tilstand som skal behandles. Vanlig oppnås dog tilfredsstillende resultater med en dose på ca. 0,01 til 50 mg/kg kroppsvekt. Denne dose kan om nodvendig tilfores i 2 til 4 del^dosér eller også som retardform. For storre pattedyr ligger dagsdosen ved omtrent 0,5 til 100 mg. Således inneholder f.eks. deldoser for oral tilforsel omtrent 0,12 til 7 mg av forbindelsene med formel I ved siden av faste eller flytende bærersubstanser. The compounds of formula I and their pharmacologically tolerable acid addition salts have not previously been described in the literature. They are distinguished by interesting pharmacodynamic properties and can therefore be used as medicine. In particular, the compounds of formula I are capable of inhibiting the secretion of the luteinizing hormone. Thus, in the functional ovulation inhibition test in rats, the compounds of formula I in doses of 0.05 to 0.5 mg/kg administered at noon on the day of proestrus to virginal rats inhibit the ovulation expected during the following night. Due to their inhibitory effect on the secretion of the luteinizing hormone, the substances can be used to influence the functions of the ovary or testicle or organ functions dependent thereon, e.g. for affecting the prostate. The doses used naturally vary depending on the species and substance, method of administration and the condition to be treated. Usually, however, satisfactory results are achieved with a dose of approx. 0.01 to 50 mg/kg body weight. This dose can, if necessary, be given in 2 to 4 divided doses or also as a slow-release form. For larger mammals, the daily dose is approximately 0.5 to 100 mg. Thus contains e.g. partial doses for oral administration of about 0.12 to 7 mg of the compounds of formula I in addition to solid or liquid carrier substances.
Videre har forbindelsene med formel I egenskaper som er typiskeFurthermore, the compounds of formula I have properties that are typical
for antidepresaya. F.eks. viser forbindelsene i dyreforsok med rotter tetrabenazin antagonistiske virkninger og hemmer f.eks. 1 dose på 0,05 til 40 mg/kg kroppsvekt i.p. den kataleptiske tilstand (holdningsstivhet), som er fremkalt ved tilforsel av tetrabenazin i rotter. for antidepressants. E.g. In animal experiments with rats, the compounds show tetrabenazine antagonistic effects and inhibit e.g. 1 dose of 0.05 to 40 mg/kg body weight i.p. the cataleptic state (postural rigidity) induced by the administration of tetrabenazine in rats.
På grunn av deres antidepressive egenskaper er forbindelseneDue to their antidepressant properties, the compounds are
egnet for behandling av depresjoner av forskjelligste type. De doser som anvendes varier selvfolgelig alt etter arten av substansen, tilforselsmåten og den tilstand som skal behandles. Vanlig oppnås dog tilfredsstillende resultater med en dose på ca. 0,05 til suitable for the treatment of depression of various types. The doses used naturally vary according to the nature of the substance, the method of administration and the condition to be treated. Usually, however, satisfactory results are achieved with a dose of approx. 0.05 more
20 mg/kg kroppsvekt. Denne dose kan om nodvendig tilfores i20 mg/kg body weight. This dose can, if necessary, be administered in
2 til 4 deldoser eller også som retardform. For storre pattedyr blir dagsdose ved omtrent 3 til 150 mg. Således inneholder f.eks. deldosene for oral tilforsel omtrent 0,7 til 75.mg av forbindelsene 2 to 4 partial doses or also as a slow-release form. For larger mammals, the daily dose is approximately 3 to 150 mg. Thus contains e.g. the partial doses for oral administration approximately 0.7 to 75 mg of the compounds
med formel I ved siden av faste eller bærersubstanser.with formula I next to solid or carrier substances.
Som legemiddel kan forbindelsene med formel I henholdsvisAs drugs, the compounds of formula I can respectively
deres fysiologisk tålbare syreaddisjonssalter tilfores alene eller i passende preparatfprm med farmakologisk indifferente hjelpestoffer. I den utstrekning fremstillingen av utgangsforbindelsene ikke er beskrevet, er disse kjente eller kan fremstilles etter i og for seg kjente metoder henholdsvis analogt med de her beskrevne eller analogt med i og for seg kjente fremgangsmåter. their physiologically tolerable acid addition salts are administered alone or in suitable preparations with pharmacologically indifferent excipients. To the extent that the preparation of the starting compounds is not described, these are known or can be prepared according to per se known methods, respectively analogous to those described here or analogous to per se known methods.
I de etterfSigende eksempler illustreres oppfinnelsen nærmere. Alle temperaturangivelser er i °C. The following examples illustrate the invention in more detail. All temperature indications are in °C.
EKSEMPEL 1; 4-^9^10=dihydro 40-me tyl - 4H-ben zo/3 L 5_7- cykloiieptaEXAMPLE 1; 4-^9^10=dihydro 40-methyl - 4H-benzo/3 L 5_7- cycloiliepta
En ISsning av 17,0 g 9,l0-dihydro-10-metyl-4-(l-metyl-4-piperdyl)-4H-benzo/5,57cykloh;epta^^2-^7tiofen-4-ol i 350 ml isopropanol og 350 ml 7 N isopropanolisk hydrogenkloridlSsning oppvarmes i 4 timer ved koketemperatur, inndampes til tSrrhet, resten opptas i 150 A solution of 17.0 g of 9,10-dihydro-10-methyl-4-(1-methyl-4-piperdyl)-4H-benzo[5,57cyclohepta^^2-^7thiophen-4-ol in 350 ml of isopropanol and 350 ml of 7 N isopropanolic hydrogen chloride solution are heated for 4 hours at boiling temperature, evaporated to dryness, the residue is taken up in 150
ml vann, innstilles alkalisk med konsentrert natronlut og utrystes med metylenklorid.Ekstraktene vaskes med vann, torres over kaliumkarbonat, avfarges med dyrekull og inndampes. Den olje-aktige rest som blir tilbake av den i overskriften nevnte forbindelse overfores i hydrokloridet i etanol (smeltepunkt av hydrokloridet av den i overskriften nevnte forbindelse: spalting fra 210°C (fra aceton/etanol). ml of water, made alkaline with concentrated caustic soda and shaken off with methylene chloride. The extracts are washed with water, dried over potassium carbonate, decolorized with animal charcoal and evaporated. The oily residue that remains of the compound mentioned in the title is transferred to the hydrochloride in ethanol (melting point of the hydrochloride of the compound mentioned in the title: cleavage from 210°C (from acetone/ethanol).
Utgangsmaterialet kan fremstilles på fSigende måte:The starting material can be produced in the following way:
a) Til suspensjonen av 4,5 g pulverisert natriummetylat i 100 ml vannfritt dimetylformamid tildryppes en ISsning av 10,0 g 2-acetyltiofen og 21,0 g dietyl-o-cyanbenzylfosfonat i 70 ml vannfritt dimetylformamid ved 20 til 30°C under nitrogenatmosfære, det omrSres videre i 2 timer ved 40°C og i 2 timer ved 100°C, reaksjonsblandingen avkjSles til romtemperatur og fortynnes med a) To the suspension of 4.5 g of powdered sodium methylate in 100 ml of anhydrous dimethylformamide is added dropwise an ice solution of 10.0 g of 2-acetylthiophene and 21.0 g of diethyl-o-cyanobenzylphosphonate in 70 ml of anhydrous dimethylformamide at 20 to 30°C under a nitrogen atmosphere , it is further stirred for 2 hours at 40°C and for 2 hours at 100°C, the reaction mixture is cooled to room temperature and diluted with
600 ml isblandet vann. Kondensasjonsproduktet ekstraheres med eter, uttrekket vaskes noytralt med vann, torres over kaliumkarbonat og inndampes. Inndampningsresten kromatograferes gjennom 110 g silikagel med en blanding av benzen/petroleter (1:4). Det som hovedfraksjon isolerte 2-/2-(2-tienyl)-l-propenyl7 benzonitril (nD =1,6460, kokepunktQ 1=165-175°C) anvendes direkte videre uten ytterligere rensing. 600 ml ice mixed water. The condensation product is extracted with ether, the extract is washed neutrally with water, dried over potassium carbonate and evaporated. The evaporation residue is chromatographed through 110 g of silica gel with a mixture of benzene/petroleum ether (1:4). The 2-(2-(2-thienyl)-1-propenyl7 benzonitrile isolated as the main fraction (nD = 1.6460, boiling point Q 1 = 165-175°C) is used directly further without further purification.
b) En losning av 14,0 g av det ovennevnte produkt i 400 ml etanol hydrogeneres i nærvær av 4,0 g 5% palladium på aluminium-oksyd i.24 timer ved 100°C og 20 ato. Etter filtrering gjennom diatomerjord inndampes losningen til torrhet og det som olje-aktig rest tilbakeblivende 2-/2-(2-tienyl)propyl7-benzonitril b) A solution of 14.0 g of the above product in 400 ml of ethanol is hydrogenated in the presence of 4.0 g of 5% palladium on aluminum oxide for 24 hours at 100°C and 20 at. After filtration through diatomaceous earth, the solution is evaporated to dryness and the oily residue remaining 2-/2-(2-thienyl)propyl7-benzonitrile
. omsettes videre uten spesiell rensing.. is traded on without special purification.
c) Til blandingen av 24,0 g kaliumhydroksyd i 60 ml dietylen-glykol-monométyieter tilsettes langsomt 12,0 g av det ovennevnte c) To the mixture of 24.0 g of potassium hydroxide in 60 ml of diethylene glycol monomethyl ether, slowly add 12.0 g of the above
produkt ved 100°C. Reaksjonsblåndingen omrores nå i 6 timer ved 160°C, avkjoles til ca. 70°C og uthelles på 300 ml varmt vann. Etter avkjoling vaskes den erholdte losning med toluen, syres med konsentrert saltsyre og utrystes med eter. De eteriske ekstrakter vaskes med vann, torres over magnesiumsulfat og inndampes. Den som rest tilbakeblivende 2-/2-(2-tienyl) propyl/benzosyre krystalliseres fra heksan. Smeltepunkt: 66 product at 100°C. The reaction mixture is now stirred for 6 hours at 160°C, cooled to approx. 70°C and poured into 300 ml of hot water. After cooling, the solution obtained is washed with toluene, acidified with concentrated hydrochloric acid and shaken out with ether. The ethereal extracts are washed with water, dried over magnesium sulphate and evaporated. The remaining 2-(2-(2-thienyl)propyl/benzoic acid is crystallized from hexane. Melting point: 66
til 68°C.to 68°C.
d) En blanding av 10,0 g av den ovennevnte syre og 100 g polyfosforsyre oppvarmes i 45 min. ved 130°C, avkjoles til 90°C og d) A mixture of 10.0 g of the above-mentioned acid and 100 g of polyphosphoric acid is heated for 45 min. at 130°C, cooled to 90°C and
uthelles på 500 ml vann. Den erholdte losning utrystes med metylenklorid, den organiske losning vaskes med fortynnet natrium-karbonatlosning og med vann, torres over natriumsulfat og inndampes. Inndampningsresten destilleres i hoyvakuum, hvorved 9,10-dihydro-lp-metyl-4H-benzo/3,57cyklohepta/I,2-b7tiofen-4-on destillerer over ved 160 til 165°C/0,1 torr. Smeltepunkt: 67 poured into 500 ml of water. The solution obtained is shaken with methylene chloride, the organic solution is washed with dilute sodium carbonate solution and with water, dried over sodium sulphate and evaporated. The evaporation residue is distilled in high vacuum, whereby 9,10-dihydro-1p-methyl-4H-benzo/3,57cyclohepta/1,2-b7thiophen-4-one distills over at 160 to 165°C/0.1 torr. Melting point: 67
til 68°C (fra eter).to 68°C (from ether).
e) 4,8. g med jod aktivert magnesium overdekkes med 60 ml vannfritt tetrahydrofuran og anetses med noen dråper etylenbromid. En e) 4.8. g of iodine-activated magnesium is covered with 60 ml of anhydrous tetrahydrofuran and annealed with a few drops of ethylene bromide. One
losning av 25,0 g 4-klor-l-metyl-piperidin i 160 ml vannfritt tetrahydrofuran tildryppes nå slik at losningsmidlet hele tiden koker, og det omrores deretter i 2 timer ved koketemperaturen. Reaksjonsblandingen avkjoles til 10°C og tilsettes ved denne temperatur dråpevis en losning av 20,0 g 9,lO-dihydro-10-metyl-4H-benzo/4\ 57cyklohepta/I, 2-b7tiof en-4-on i 100 ml vannfritt tetrahydrofuran. Etter 1,5 times ytterligere omroring ved romtemperatur og 30 min. ved koketemperatur avkjoles reaksjonsblandingen, uthelles på 300 ml 20% ammoniumkloridlosning og denoorganiske fase fraskilles. Den vandige losning utrystes med metylenklorid. De forenede organiske losninger vaskes med vann, torres over; nåtriumsulfat og inndampes. Den som rest erholdte 9,lO-dihydro-l-metyl-4-(l-metyl-4-piperidyl)-4H-benzo/4,57 cyklohepta/I,2-b7tiofen-4-ol omkrystalliseres to ganger fra isopropanol. Smeltepunkt 177 til 178°C. solution of 25.0 g of 4-chloro-1-methyl-piperidine in 160 ml of anhydrous tetrahydrofuran is now added dropwise so that the solvent constantly boils, and it is then stirred for 2 hours at the boiling temperature. The reaction mixture is cooled to 10°C and at this temperature a solution of 20.0 g of 9,10-dihydro-10-methyl-4H-benzo[4]cyclohepta[1,2-b]thiophen-4-one in 100 ml is added dropwise anhydrous tetrahydrofuran. After 1.5 hours of further stirring at room temperature and 30 min. at boiling temperature, the reaction mixture is cooled, poured onto 300 ml of 20% ammonium chloride solution and the inorganic phase is separated. The aqueous solution is shaken with methylene chloride. The combined organic solutions are washed with water, dried over; sodium sulfate and evaporate. The 9,10-dihydro-1-methyl-4-(1-methyl-4-piperidyl)-4H-benzo/4,57 cyclohepta/1,2-b7thiophen-4-ol obtained as a residue is recrystallized twice from isopropanol. Melting point 177 to 178°C.
EKSEMPEL 2: 4-jlO-etyl-9L10-dihydro-4^ EXAMPLE 2: 4-n10-ethyl-9N10-dihydro-4N
tiofen-4-yliden2-l-metylpiperid^nthiophen-4-ylidene2-1-methylpiperidine
En losning av 15,0 g 10-etyl-9,10-dihydro-4-(l-metyl-4-piperidyl)-4H-benzo/3,57cyklohepta/1,2-b7tiofen-4-ol i 450 ml 3 ,'5 N isopropanolisk hydrogenkloridlosning oppvarmes i 4 timer ved koketemperatur og den etter opparbeidelse av reaksjonsblandingen i overskriften nevnte forbindelse overfores i sitt hydrogen-fumarat. Smeltepunkt: 220 til 221°C (fra metanol/etanol). A solution of 15.0 g of 10-ethyl-9,10-dihydro-4-(1-methyl-4-piperidyl)-4H-benzo/3,57cyclohepta/1,2-b7thiophen-4-ol in 450 ml 3 .5 N isopropanolic hydrogen chloride solution is heated for 4 hours at boiling temperature and, after working up the reaction mixture in the title, the compound mentioned in the title is transferred into its hydrogen fumarate. Melting point: 220 to 221°C (from methanol/ethanol).
Utgangsmaterial:Starting material:
a) 2-/2-(2-tienyl)-l-butenyl7benzonitril, rensing av rå--produktet ved destillasjon, kokepunktg 2 = 150 til 153°C. b) 2-/2-(2-tienyl)butyl7benzonitril, renset ved destillasjon, kokepunktQ 1 = 128 til 132°C. c) 2-/2-(2-tienyl)-butyl7benzosyre, videre forarbeides i rå tilstand. a) 2-(2-(2-thienyl)-1-butenyl7benzonitrile, purification of the crude product by distillation, boiling point g 2 = 150 to 153°C. b) 2-(2-(2-thienyl)butyl7benzonitrile, purified by distillation, boiling point Q 1 = 128 to 132°C. c) 2-/2-(2-thienyl)-butyl-7-benzoic acid, further processed in the raw state.
d) lO-etyl-9,lO-dihydro-4H-benzo/3,5^ cyklohepta/I,2-b7tiofen-4-d) 10-ethyl-9,10-dihydro-4H-benzo/3,5-cyclohepta/1,2-b7thiophene-4-
on, renset ved destillasjon, kokepunktQ ^ til015= 185 til on, purified by distillation, boiling pointQ ^ to015= 185 to
'/ 190°C. e) 10-etyl-9,lO-dihydro-4-(l-metyl-4-piperidyl)-4H-benzo/3,57-cyklohepta/I,2-b7tiofen-4-ol, fremstilt fra 2,4 g magnesium, 190°C. e) 10-ethyl-9,10-dihydro-4-(1-methyl-4-piperidyl)-4H-benzo[3,57-cyclohepta]1,2-b7thiophen-4-ol, prepared from 2.4 g magnesium,
12,5 g 4-klor-l-metylpiperidin og 10 g 10-etyl-9,10-dihydro-4H-benzo/3,57cyklohepta/I,2-b7tiofen-4-on i 150 ml tetrahydro- 12.5 g of 4-chloro-1-methylpiperidine and 10 g of 10-ethyl-9,10-dihydro-4H-benzo/3,57cyclohepta/1,2-b7thiophen-4-one in 150 ml of tetrahydro-
u. ' furan. Smeltepunkt 145 til 148°C (fra isopropanol).u. ' furan. Melting point 145 to 148°C (from isopropanol).
EKSEMPEL 3: 4-U0=metyl-4H-benzo/3^57cyklohep EXAMPLE 3: 4-U0=methyl-4H-benzo/3^57cyclohep
yliden)-l-metylpiperidinylidene)-1-methylpiperidine
I henhold til eksempel 1 fremstilles fra 1,0 g 10-metyl-4-(l-metyl-4-piperidyl )-4H-benzo/3, 5_7cyklohepta/1, 2-t>7tiof en-4-ol i 40 ml 3,5 N isopropanolisk hydrogenkloridlSsnirig den i overskriften nevnte forbindelse. Smeltepunkt av hydrokloridet: According to example 1, 1.0 g of 10-methyl-4-(1-methyl-4-piperidyl)-4H-benzo[3,5-7cyclohepta[1,2-t>7thiophene-4-ol] is prepared in 40 ml 3.5 N isopropanolic hydrogen chloride with the compound mentioned in the title. Melting point of the hydrochloride:
spalting fra 2 95°C.cleavage from 2 95°C.
Utgangsmaterialet kan fremstilles på fSigende måte:The starting material can be produced in the following way:
a) En blanding av 20,0 g 9, iO-dihydro-?lp-metyl-4H-benzo/3, 5_7 cyklohepta/I, 2-b/tiofen-4-on, 15,6 g N-bromsup;cinimid og 0,5 g a) A mixture of 20.0 g of 9,10-dihydro-β-methyl-4H-benzo[3,5-7 cyclohepta[1,2-b]thiophen-4-one, 15.6 g of N-bromosup;cinimide and 0.5 g
■ .dibenzdyl per oksyd i, 15 0 ml' vannfr i tt'; karbon té traklor id ■ .dibenzdyl per oxide in, 15 0 ml' anhydrous in tt'; carbon tea trachlor id
. oppvarmes langsomt til 70°C, hvorved en eksotermisk reaksjon igangsettes og det oppvarmes deretter enda i 2 timer til . is slowly heated to 70°C, whereby an exothermic reaction is initiated and it is then heated for a further 2 hours
kokning. Etter avkjSling frafiltreres det utskilte succinimid,. ^filtratet inndampes til tSrrhet og resten oppvarmes til koking boiling. After cooling, the secreted succinimide is filtered off. The filtrate is evaporated to tSrrhet and the residue is heated to boiling
2 timer i 130 ml trietylamin. LSsningsmidlet avdampes,2 hours in 130 ml of triethylamine. The solvent is evaporated,
resten loses i metylenklorid og vann, den organiske fase fraskilles og vaskes med 2 N saltsyre og deretter med vann. Etter avdamping av ISsningsmidlet destilleres resten i hSy-vakuum, hvorved 10-metyl-4H-benzo/4~, 5_7cyklohepta/I,<2-b7-■ s.. : tiofen-4-on destillerer over ved 205 tii. 210°C/0,1 torr. Smeltepunkt fra eter: 75 til 76°C. the residue is dissolved in methylene chloride and water, the organic phase is separated and washed with 2 N hydrochloric acid and then with water. After evaporation of the solvent, the residue is distilled in hSy vacuum, whereby 10-methyl-4H-benzo/4~,5_7cyclohepta/I,<2-b7-■ s..: thiophen-4-one distills over at 205 tii. 210°C/0.1 torr. Melting point from ether: 75 to 76°C.
b) 10-metyl-4-(l-metyl-4-piperidyl)-4H-benzo/3,57cyklohepta/I,2-ty7-tiofen^4-ol, fremstilt fra 1,2 g magnesium, 6,8 g 4-klor-l-metyl<-^ J) b) 10-methyl-4-(1-methyl-4-piperidyl)-4H-benzo[3,57cyclohepta]1,2-thy7-thiophen^4-ol, prepared from 1.2 g of magnesium, 6.8 g 4-chloro-1-methyl<-^ J)
piperidin og 5,4 g 10-metyl-4H-benzo/3, 5_7cyklohepta/I, 2- h/tiofen-4-on i 50 ml vannfritt tetrahydrofuran, videreforarbeides i rå tilstand. piperidine and 5.4 g of 10-methyl-4H-benzo[3,5_7cyclohepta[1,2-h]thiophen-4-one in 50 ml of anhydrous tetrahydrofuran, are further processed in the crude state.
Analogt med eksempel 1 kan også de folgende 10-alkyl-4-(1-alkyl-4-piperidyliden)-4H-benzo/3,57-cyklohepta/I,2-b7tiofenderivater erholdes ved vannavspalting fra tilsvarende lO-alkyl-4-(1-alkyl-4-piperidyl)-4H-benzo/3,57cyklohepta/I,2-b7tiofen-4-ol- Analogous to example 1, the following 10-alkyl-4-(1-alkyl-4-piperidylidene)-4H-benzo/3,57-cyclohepta/1,2-b7thiophene derivatives can also be obtained by splitting off water from the corresponding 10-alkyl-4- (1-alkyl-4-piperidyl)-4H-benzo[3,57cyclohepta]1,2-b7thiophen-4-ol-
derivater: derivatives:
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO750579A NO750579L (en) | 1975-02-20 | 1975-02-20 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO750579A NO750579L (en) | 1975-02-20 | 1975-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO750579L true NO750579L (en) | 1976-08-23 |
Family
ID=19882096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO750579A NO750579L (en) | 1975-02-20 | 1975-02-20 |
Country Status (1)
Country | Link |
---|---|
NO (1) | NO750579L (en) |
-
1975
- 1975-02-20 NO NO750579A patent/NO750579L/no unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3420851A (en) | Novel dibenzoxepines | |
NO325076B1 (en) | Nonsteroidal (hetero) cyclic-substituted acylanilides with mixed progestogen and androgenic action, their preparation, pharmaceutical compositions comprising them and their use in the preparation of pharmaceutical preparations | |
NO884008L (en) | PROCEDURE FOR PREPARING 3,7-DIAZABICYCLO (3,3,1) NON-COMPOUNDS. | |
NO142865B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF NEW THERAPEUTIC ACTIVE CARBZOLS | |
NO129043B (en) | ||
NO812557L (en) | PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 9-AMINO-1-HYDROXYOCTAHYDROBENZO (C) QUINOLINE DERIVATIVES | |
US4247706A (en) | Dibenzothiepin derivatives and a process for producing the same | |
IL40861A (en) | Thiepin and oxepin derivatives and their preparation | |
NO140978B (en) | ANALOGICAL PROCEDURE FOR PREPARATION OF THERAPEUTICALLY ACTIVE ISOKINOLINE DERIVATIVES | |
GB2185743A (en) | 8 alpha -Acylaminoergoline's | |
NO750579L (en) | ||
GB2056435A (en) | Novel Tetrahydropyridine and Piperidine Substituted Benzofuranes and Related Compounds | |
DK160043B (en) | ANALOGY PROCEDURE FOR PREPARING N-ALK-2-EN-4-YN-YL-BENZOTHIENYLALKYLAMINES OR ACID ADDITION SALTS THEREOF | |
DK159110B (en) | 4H-BENZO (4,5) CYCLOHEPTA (1,2-B) THIOPHENDER DERIVATIVES, PROCEDURES FOR PREPARING IT, AND PHARMACEUTICAL PREPARATIONS CONTAINING THE DERIVATIVES | |
SU741798A3 (en) | Method of preparing octahydropyridoindolylbenzazepin derivatives or their salts | |
US3651051A (en) | Benzo(b)benzofurano(2 3-e)oxepines | |
US4223035A (en) | Treating prostate hypertrophy with 4-(4H-benzo[4,5]cyclohepta[1,2-b]thiophen-4-ylidene)-1-methylpiperidines | |
NO743135L (en) | ||
US3428677A (en) | Chemical compounds and methods of preparing same | |
NO175780B (en) | Analogous Process for the Preparation of Therapeutically Active Substituted Dibenzofurans | |
US4136116A (en) | Tricyclic compounds | |
US3306934A (en) | 5-(aminopropylidene)-and 5-hydroxy-5-(aminopropyl)-3-dialkylsulfamoyl-5h-dibenzo[a,d] cycloheptenes | |
NO143169B (en) | WALL CONSOLE TO FIX PRIOR MARKET FITTINGS | |
Walker et al. | Synthesis of 10, 11-dihydro-5, 10-ethano-5H-dibenzo [a, d] cycloheptenes with various side chains at position 12 | |
GB2145082A (en) | Process for the preparation of 2,3-dihydro-[4H)-1 -benzopyran-4-one and 2,3,5,6,7,8- hexahydro-(4H)-1-benzopyran-4,5-dione derivatives |